FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastroenterology, ophthalmology, anti-diabetics, cardiovascular care, respiratory care, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured oral rehydration solution powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zifi-0, Zocon, Mycoderm, Zathrin, Victofol, Cotaryl, Ziglim-M, Amodep-AT, MumMum 1, Victofol Injection, Simyl MCT, Victofol " C, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
Visit company website
5 years, 5 months ago
FDC Limited is currently in a long term uptrend where the price is trading 10.4% above its 200 day moving average.
From a valuation standpoint, the stock is 24.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
FDC Limited's total revenue rose by 5.9% to $3B since the same quarter in the previous year.
Its net income has increased by 1.5% to $752M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.7% to $1B since the same quarter in the previous year.
Based on the above factors, FDC Limited gets an overall score of 4/5.